BCL2 and thyroid gland carcinoma: These cell lines can be targeted by GX15-070 (obatoclax), a pan-inhibitor of the BCL-2 family, while ABT-263 was modestly effective [53] which generally showed the suitability of BH3 mimetics for treatment of thyroid carcinoma cells.